08:54 AM EDT, 06/16/2026 (MT Newswires) -- BioAge Labs ( BIOA ) dosed the first participant in a phase 2 proof-of-concept trial evaluating BGE-102, an oral NLRP3 inhibitor, in patients at elevated cardiovascular risk, the company said Tuesday.

The randomized placebo-controlled trial will enroll about 160 adults with obesity, elevated systemic inflammation, and at least one additional cardiovascular risk factor, BioAge Labs ( BIOA ) said.

Participants will receive placebo or once-daily BGE-102 at doses of 30 mg, 60 mg or 90 mg for 12 weeks. The primary endpoint is the percent change in high-sensitivity C-reactive protein, or hsCRP, a marker of inflammation, according to the company.

BioAge Labs ( BIOA ) said the study is intended to support dose selection for phase 3 development, with topline data expected in H2.